Mass spectrometry-based proteomics as an emerging tool in clinical laboratories

Clinical Proteomics

Review

Alemayehu Godana Birhanu¹ 

[1] Institute of Biotechnology, Addis Ababa University, P.O. Box 1176, Addis Ababa, Ethiopia;

关键词: Mass spectrometry;    Clinical proteomics;    Diagnosis;    Biomarker;    Prognosis;    Microbiology;    Cancer;    Metabolic Disorders;   

DOI  :  10.1186/s12014-023-09424-x

 received in 2023-02-08, accepted in 2023-08-03,  发布年份 2023

来源: Springer

【 摘 要 】

Mass spectrometry (MS)-based proteomics have been increasingly implemented in various disciplines of laboratory medicine to identify and quantify biomolecules in a variety of biological specimens. MS-based proteomics is continuously expanding and widely applied in biomarker discovery for early detection, prognosis and markers for treatment response prediction and monitoring. Furthermore, making these advanced tests more accessible and affordable will have the greatest healthcare benefit.This review article highlights the new paradigms MS-based clinical proteomics has created in microbiology laboratories, cancer research and diagnosis of metabolic disorders. The technique is preferred over conventional methods in disease detection and therapy monitoring for its combined advantages in multiplexing capacity, remarkable analytical specificity and sensitivity and low turnaround time.Despite the achievements in the development and adoption of a number of MS-based clinical proteomics practices, more are expected to undergo transition from bench to bedside in the near future. The review provides insights from early trials and recent progresses (mainly covering literature from the NCBI database) in the application of proteomics in clinical laboratories.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 图 表 】

12888_2023_5113_Article_IEq2.gif